Chronic Lymphocytic Leukemia Drugs Market, Global Outlook and Forecast 2022-2028

January 2022 | 105 pages | ID: CC4B1A5A79BEEN
Market Monitor Global

Abstracts

Chronic Lymphocytic Leukemia (CLL) is a type of hematological malignancy marked by excessive proliferation of abnormal white blood cells. CLL predominantly affects the B-cell lymphocytes which are involved in the production of antibodies to fight against infections and foreign antigens. Rising incidence of CLL coupled with a high rate of mortality, demonstrates the unmet market need for better therapeutics.

This report contains market size and forecasts of Chronic Lymphocytic Leukemia Drugs in Global, including the following market information:

Global Chronic Lymphocytic Leukemia Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Chronic Lymphocytic Leukemia Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Oral Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Chronic Lymphocytic Leukemia Drugs include AbbVie, AstraZeneca plc, Biogen Idec, Celgene Corporation, Cyclacel Pharmaceuticals, F. Hoffmann-La Roche AG, Genentech Inc, Genmab and Genzyme Corporation, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Chronic Lymphocytic Leukemia Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Chronic Lymphocytic Leukemia Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Chronic Lymphocytic Leukemia Drugs Market Segment Percentages, by Type, 2021 (%)

• Oral Drugs
• Intravenous Drugs
• Others

Global Chronic Lymphocytic Leukemia Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Chronic Lymphocytic Leukemia Drugs Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic
• Others

Global Chronic Lymphocytic Leukemia Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Chronic Lymphocytic Leukemia Drugs Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Chronic Lymphocytic Leukemia Drugs revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Chronic Lymphocytic Leukemia Drugs revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• AbbVie
• AstraZeneca plc
• Biogen Idec
• Celgene Corporation
• Cyclacel Pharmaceuticals
• F. Hoffmann-La Roche AG
• Genentech Inc
• Genmab
• Genzyme Corporation
• Gilead Sciences
• GlaxoSmithKline Plc
• Infinity Pharmaceuticals
• MorphoSys AG
• Novartis AG
• Noxxon Pharma AG
• Teva Pharmaceutical Industries Ltd
• TG Therapeutics

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Chronic Lymphocytic Leukemia Drugs Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Chronic Lymphocytic Leukemia Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA DRUGS OVERALL MARKET SIZE

2.1 Global Chronic Lymphocytic Leukemia Drugs Market Size: 2021 VS 2028
2.2 Global Chronic Lymphocytic Leukemia Drugs Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Chronic Lymphocytic Leukemia Drugs Players in Global Market
3.2 Top Global Chronic Lymphocytic Leukemia Drugs Companies Ranked by Revenue
3.3 Global Chronic Lymphocytic Leukemia Drugs Revenue by Companies
3.4 Top 3 and Top 5 Chronic Lymphocytic Leukemia Drugs Companies in Global Market, by Revenue in 2021
3.5 Global Companies Chronic Lymphocytic Leukemia Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Chronic Lymphocytic Leukemia Drugs Players in Global Market
  3.6.1 List of Global Tier 1 Chronic Lymphocytic Leukemia Drugs Companies
  3.6.2 List of Global Tier 2 and Tier 3 Chronic Lymphocytic Leukemia Drugs Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Chronic Lymphocytic Leukemia Drugs Market Size Markets, 2021 & 2028
  4.1.2 Oral Drugs
  4.1.3 Intravenous Drugs
  4.1.4 Others
4.2 By Type - Global Chronic Lymphocytic Leukemia Drugs Revenue & Forecasts
  4.2.1 By Type - Global Chronic Lymphocytic Leukemia Drugs Revenue, 2017-2022
  4.2.2 By Type - Global Chronic Lymphocytic Leukemia Drugs Revenue, 2023-2028
  4.2.3 By Type - Global Chronic Lymphocytic Leukemia Drugs Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Chronic Lymphocytic Leukemia Drugs Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Clinic
  5.1.4 Others
5.2 By Application - Global Chronic Lymphocytic Leukemia Drugs Revenue & Forecasts
  5.2.1 By Application - Global Chronic Lymphocytic Leukemia Drugs Revenue, 2017-2022
  5.2.2 By Application - Global Chronic Lymphocytic Leukemia Drugs Revenue, 2023-2028
  5.2.3 By Application - Global Chronic Lymphocytic Leukemia Drugs Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Chronic Lymphocytic Leukemia Drugs Market Size, 2021 & 2028
6.2 By Region - Global Chronic Lymphocytic Leukemia Drugs Revenue & Forecasts
  6.2.1 By Region - Global Chronic Lymphocytic Leukemia Drugs Revenue, 2017-2022
  6.2.2 By Region - Global Chronic Lymphocytic Leukemia Drugs Revenue, 2023-2028
  6.2.3 By Region - Global Chronic Lymphocytic Leukemia Drugs Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Chronic Lymphocytic Leukemia Drugs Revenue, 2017-2028
  6.3.2 US Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
  6.3.3 Canada Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
  6.3.4 Mexico Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Chronic Lymphocytic Leukemia Drugs Revenue, 2017-2028
  6.4.2 Germany Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
  6.4.3 France Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
  6.4.4 U.K. Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
  6.4.5 Italy Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
  6.4.6 Russia Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
  6.4.7 Nordic Countries Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
  6.4.8 Benelux Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Chronic Lymphocytic Leukemia Drugs Revenue, 2017-2028
  6.5.2 China Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
  6.5.3 Japan Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
  6.5.4 South Korea Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
  6.5.5 Southeast Asia Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
  6.5.6 India Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Chronic Lymphocytic Leukemia Drugs Revenue, 2017-2028
  6.6.2 Brazil Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
  6.6.3 Argentina Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Chronic Lymphocytic Leukemia Drugs Revenue, 2017-2028
  6.7.2 Turkey Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
  6.7.3 Israel Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
  6.7.4 Saudi Arabia Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028
  6.7.5 UAE Chronic Lymphocytic Leukemia Drugs Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 AbbVie
  7.1.1 AbbVie Corporate Summary
  7.1.2 AbbVie Business Overview
  7.1.3 AbbVie Chronic Lymphocytic Leukemia Drugs Major Product Offerings
  7.1.4 AbbVie Chronic Lymphocytic Leukemia Drugs Revenue in Global Market (2017-2022)
  7.1.5 AbbVie Key News
7.2 AstraZeneca plc
  7.2.1 AstraZeneca plc Corporate Summary
  7.2.2 AstraZeneca plc Business Overview
  7.2.3 AstraZeneca plc Chronic Lymphocytic Leukemia Drugs Major Product Offerings
  7.2.4 AstraZeneca plc Chronic Lymphocytic Leukemia Drugs Revenue in Global Market (2017-2022)
  7.2.5 AstraZeneca plc Key News
7.3 Biogen Idec
  7.3.1 Biogen Idec Corporate Summary
  7.3.2 Biogen Idec Business Overview
  7.3.3 Biogen Idec Chronic Lymphocytic Leukemia Drugs Major Product Offerings
  7.3.4 Biogen Idec Chronic Lymphocytic Leukemia Drugs Revenue in Global Market (2017-2022)
  7.3.5 Biogen Idec Key News
7.4 Celgene Corporation
  7.4.1 Celgene Corporation Corporate Summary
  7.4.2 Celgene Corporation Business Overview
  7.4.3 Celgene Corporation Chronic Lymphocytic Leukemia Drugs Major Product Offerings
  7.4.4 Celgene Corporation Chronic Lymphocytic Leukemia Drugs Revenue in Global Market (2017-2022)
  7.4.5 Celgene Corporation Key News
7.5 Cyclacel Pharmaceuticals
  7.5.1 Cyclacel Pharmaceuticals Corporate Summary
  7.5.2 Cyclacel Pharmaceuticals Business Overview
  7.5.3 Cyclacel Pharmaceuticals Chronic Lymphocytic Leukemia Drugs Major Product Offerings
  7.5.4 Cyclacel Pharmaceuticals Chronic Lymphocytic Leukemia Drugs Revenue in Global Market (2017-2022)
  7.5.5 Cyclacel Pharmaceuticals Key News
7.6 F. Hoffmann-La Roche AG
  7.6.1 F. Hoffmann-La Roche AG Corporate Summary
  7.6.2 F. Hoffmann-La Roche AG Business Overview
  7.6.3 F. Hoffmann-La Roche AG Chronic Lymphocytic Leukemia Drugs Major Product Offerings
  7.6.4 F. Hoffmann-La Roche AG Chronic Lymphocytic Leukemia Drugs Revenue in Global Market (2017-2022)
  7.6.5 F. Hoffmann-La Roche AG Key News
7.7 Genentech Inc
  7.7.1 Genentech Inc Corporate Summary
  7.7.2 Genentech Inc Business Overview
  7.7.3 Genentech Inc Chronic Lymphocytic Leukemia Drugs Major Product Offerings
  7.7.4 Genentech Inc Chronic Lymphocytic Leukemia Drugs Revenue in Global Market (2017-2022)
  7.7.5 Genentech Inc Key News
7.8 Genmab
  7.8.1 Genmab Corporate Summary
  7.8.2 Genmab Business Overview
  7.8.3 Genmab Chronic Lymphocytic Leukemia Drugs Major Product Offerings
  7.8.4 Genmab Chronic Lymphocytic Leukemia Drugs Revenue in Global Market (2017-2022)
  7.8.5 Genmab Key News
7.9 Genzyme Corporation
  7.9.1 Genzyme Corporation Corporate Summary
  7.9.2 Genzyme Corporation Business Overview
  7.9.3 Genzyme Corporation Chronic Lymphocytic Leukemia Drugs Major Product Offerings
  7.9.4 Genzyme Corporation Chronic Lymphocytic Leukemia Drugs Revenue in Global Market (2017-2022)
  7.9.5 Genzyme Corporation Key News
7.10 Gilead Sciences
  7.10.1 Gilead Sciences Corporate Summary
  7.10.2 Gilead Sciences Business Overview
  7.10.3 Gilead Sciences Chronic Lymphocytic Leukemia Drugs Major Product Offerings
  7.10.4 Gilead Sciences Chronic Lymphocytic Leukemia Drugs Revenue in Global Market (2017-2022)
  7.10.5 Gilead Sciences Key News
7.11 GlaxoSmithKline Plc
  7.11.1 GlaxoSmithKline Plc Corporate Summary
  7.11.2 GlaxoSmithKline Plc Business Overview
  7.11.3 GlaxoSmithKline Plc Chronic Lymphocytic Leukemia Drugs Major Product Offerings
  7.11.4 GlaxoSmithKline Plc Chronic Lymphocytic Leukemia Drugs Revenue in Global Market (2017-2022)
  7.11.5 GlaxoSmithKline Plc Key News
7.12 Infinity Pharmaceuticals
  7.12.1 Infinity Pharmaceuticals Corporate Summary
  7.12.2 Infinity Pharmaceuticals Business Overview
  7.12.3 Infinity Pharmaceuticals Chronic Lymphocytic Leukemia Drugs Major Product Offerings
  7.12.4 Infinity Pharmaceuticals Chronic Lymphocytic Leukemia Drugs Revenue in Global Market (2017-2022)
  7.12.5 Infinity Pharmaceuticals Key News
7.13 MorphoSys AG
  7.13.1 MorphoSys AG Corporate Summary
  7.13.2 MorphoSys AG Business Overview
  7.13.3 MorphoSys AG Chronic Lymphocytic Leukemia Drugs Major Product Offerings
  7.13.4 MorphoSys AG Chronic Lymphocytic Leukemia Drugs Revenue in Global Market (2017-2022)
  7.13.5 MorphoSys AG Key News
7.14 Novartis AG
  7.14.1 Novartis AG Corporate Summary
  7.14.2 Novartis AG Business Overview
  7.14.3 Novartis AG Chronic Lymphocytic Leukemia Drugs Major Product Offerings
  7.14.4 Novartis AG Chronic Lymphocytic Leukemia Drugs Revenue in Global Market (2017-2022)
  7.14.5 Novartis AG Key News
7.15 Noxxon Pharma AG
  7.15.1 Noxxon Pharma AG Corporate Summary
  7.15.2 Noxxon Pharma AG Business Overview
  7.15.3 Noxxon Pharma AG Chronic Lymphocytic Leukemia Drugs Major Product Offerings
  7.15.4 Noxxon Pharma AG Chronic Lymphocytic Leukemia Drugs Revenue in Global Market (2017-2022)
  7.15.5 Noxxon Pharma AG Key News
7.16 Teva Pharmaceutical Industries Ltd
  7.16.1 Teva Pharmaceutical Industries Ltd Corporate Summary
  7.16.2 Teva Pharmaceutical Industries Ltd Business Overview
  7.16.3 Teva Pharmaceutical Industries Ltd Chronic Lymphocytic Leukemia Drugs Major Product Offerings
  7.16.4 Teva Pharmaceutical Industries Ltd Chronic Lymphocytic Leukemia Drugs Revenue in Global Market (2017-2022)
  7.16.5 Teva Pharmaceutical Industries Ltd Key News
7.17 TG Therapeutics
  7.17.1 TG Therapeutics Corporate Summary
  7.17.2 TG Therapeutics Business Overview
  7.17.3 TG Therapeutics Chronic Lymphocytic Leukemia Drugs Major Product Offerings
  7.17.4 TG Therapeutics Chronic Lymphocytic Leukemia Drugs Revenue in Global Market (2017-2022)
  7.17.5 TG Therapeutics Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Chronic Lymphocytic Leukemia Drugs Market Opportunities & Trends in Global Market
Table 2. Chronic Lymphocytic Leukemia Drugs Market Drivers in Global Market
Table 3. Chronic Lymphocytic Leukemia Drugs Market Restraints in Global Market
Table 4. Key Players of Chronic Lymphocytic Leukemia Drugs in Global Market
Table 5. Top Chronic Lymphocytic Leukemia Drugs Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Chronic Lymphocytic Leukemia Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Chronic Lymphocytic Leukemia Drugs Revenue Share by Companies, 2017-2022
Table 8. Global Companies Chronic Lymphocytic Leukemia Drugs Product Type
Table 9. List of Global Tier 1 Chronic Lymphocytic Leukemia Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Chronic Lymphocytic Leukemia Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Chronic Lymphocytic Leukemia Drugs Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Chronic Lymphocytic Leukemia Drugs Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Chronic Lymphocytic Leukemia Drugs Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Chronic Lymphocytic Leukemia Drugs Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2023-2028
Table 30. AbbVie Corporate Summary
Table 31. AbbVie Chronic Lymphocytic Leukemia Drugs Product Offerings
Table 32. AbbVie Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), (2017-2022)
Table 33. AstraZeneca plc Corporate Summary
Table 34. AstraZeneca plc Chronic Lymphocytic Leukemia Drugs Product Offerings
Table 35. AstraZeneca plc Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), (2017-2022)
Table 36. Biogen Idec Corporate Summary
Table 37. Biogen Idec Chronic Lymphocytic Leukemia Drugs Product Offerings
Table 38. Biogen Idec Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), (2017-2022)
Table 39. Celgene Corporation Corporate Summary
Table 40. Celgene Corporation Chronic Lymphocytic Leukemia Drugs Product Offerings
Table 41. Celgene Corporation Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), (2017-2022)
Table 42. Cyclacel Pharmaceuticals Corporate Summary
Table 43. Cyclacel Pharmaceuticals Chronic Lymphocytic Leukemia Drugs Product Offerings
Table 44. Cyclacel Pharmaceuticals Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), (2017-2022)
Table 45. F. Hoffmann-La Roche AG Corporate Summary
Table 46. F. Hoffmann-La Roche AG Chronic Lymphocytic Leukemia Drugs Product Offerings
Table 47. F. Hoffmann-La Roche AG Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), (2017-2022)
Table 48. Genentech Inc Corporate Summary
Table 49. Genentech Inc Chronic Lymphocytic Leukemia Drugs Product Offerings
Table 50. Genentech Inc Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), (2017-2022)
Table 51. Genmab Corporate Summary
Table 52. Genmab Chronic Lymphocytic Leukemia Drugs Product Offerings
Table 53. Genmab Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), (2017-2022)
Table 54. Genzyme Corporation Corporate Summary
Table 55. Genzyme Corporation Chronic Lymphocytic Leukemia Drugs Product Offerings
Table 56. Genzyme Corporation Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), (2017-2022)
Table 57. Gilead Sciences Corporate Summary
Table 58. Gilead Sciences Chronic Lymphocytic Leukemia Drugs Product Offerings
Table 59. Gilead Sciences Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), (2017-2022)
Table 60. GlaxoSmithKline Plc Corporate Summary
Table 61. GlaxoSmithKline Plc Chronic Lymphocytic Leukemia Drugs Product Offerings
Table 62. GlaxoSmithKline Plc Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), (2017-2022)
Table 63. Infinity Pharmaceuticals Corporate Summary
Table 64. Infinity Pharmaceuticals Chronic Lymphocytic Leukemia Drugs Product Offerings
Table 65. Infinity Pharmaceuticals Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), (2017-2022)
Table 66. MorphoSys AG Corporate Summary
Table 67. MorphoSys AG Chronic Lymphocytic Leukemia Drugs Product Offerings
Table 68. MorphoSys AG Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), (2017-2022)
Table 69. Novartis AG Corporate Summary
Table 70. Novartis AG Chronic Lymphocytic Leukemia Drugs Product Offerings
Table 71. Novartis AG Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), (2017-2022)
Table 72. Noxxon Pharma AG Corporate Summary
Table 73. Noxxon Pharma AG Chronic Lymphocytic Leukemia Drugs Product Offerings
Table 74. Noxxon Pharma AG Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), (2017-2022)
Table 75. Teva Pharmaceutical Industries Ltd Corporate Summary
Table 76. Teva Pharmaceutical Industries Ltd Chronic Lymphocytic Leukemia Drugs Product Offerings
Table 77. Teva Pharmaceutical Industries Ltd Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), (2017-2022)
Table 78. TG Therapeutics Corporate Summary
Table 79. TG Therapeutics Chronic Lymphocytic Leukemia Drugs Product Offerings
Table 80. TG Therapeutics Chronic Lymphocytic Leukemia Drugs Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Chronic Lymphocytic Leukemia Drugs Segment by Type in 2021
Figure 2. Chronic Lymphocytic Leukemia Drugs Segment by Application in 2021
Figure 3. Global Chronic Lymphocytic Leukemia Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Chronic Lymphocytic Leukemia Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Chronic Lymphocytic Leukemia Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Chronic Lymphocytic Leukemia Drugs Revenue in 2021
Figure 8. By Type - Global Chronic Lymphocytic Leukemia Drugs Revenue Market Share, 2017-2028
Figure 9. By Application - Global Chronic Lymphocytic Leukemia Drugs Revenue Market Share, 2017-2028
Figure 10. By Region - Global Chronic Lymphocytic Leukemia Drugs Revenue Market Share, 2017-2028
Figure 11. By Country - North America Chronic Lymphocytic Leukemia Drugs Revenue Market Share, 2017-2028
Figure 12. US Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Chronic Lymphocytic Leukemia Drugs Revenue Market Share, 2017-2028
Figure 16. Germany Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 17. France Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Chronic Lymphocytic Leukemia Drugs Revenue Market Share, 2017-2028
Figure 24. China Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. India Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Chronic Lymphocytic Leukemia Drugs Revenue Market Share, 2017-2028
Figure 30. Brazil Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Chronic Lymphocytic Leukemia Drugs Revenue Market Share, 2017-2028
Figure 33. Turkey Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Chronic Lymphocytic Leukemia Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. AbbVie Chronic Lymphocytic Leukemia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. AstraZeneca plc Chronic Lymphocytic Leukemia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Biogen Idec Chronic Lymphocytic Leukemia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Celgene Corporation Chronic Lymphocytic Leukemia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Cyclacel Pharmaceuticals Chronic Lymphocytic Leukemia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. F. Hoffmann-La Roche AG Chronic Lymphocytic Leukemia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Genentech Inc Chronic Lymphocytic Leukemia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Genmab Chronic Lymphocytic Leukemia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Genzyme Corporation Chronic Lymphocytic Leukemia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Gilead Sciences Chronic Lymphocytic Leukemia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. GlaxoSmithKline Plc Chronic Lymphocytic Leukemia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Infinity Pharmaceuticals Chronic Lymphocytic Leukemia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. MorphoSys AG Chronic Lymphocytic Leukemia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Novartis AG Chronic Lymphocytic Leukemia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Noxxon Pharma AG Chronic Lymphocytic Leukemia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Teva Pharmaceutical Industries Ltd Chronic Lymphocytic Leukemia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. TG Therapeutics Chronic Lymphocytic Leukemia Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)